MEA Veterinary Vaccines Market: Rising incidence of food borne and zoonotic diseases in MEA countries likely to fuel the demand for attenuated live vaccines

Animal breeding remains to be one of the most fundamental agricultural activity facilitating the growth of food & beverage industry in the Middle East. Milk and meat are some of the common raw materials derived from animal husbandry activities carried out in the MEA region. Future Market Insights recently published its research report on the veterinary vaccines market in the Middle East, which stated that – rising demand for food security in the Middle East, collaborative manufacturing measures witnessed among foodmakers and suppliers, and the absence of appropriate health tracking facilities for animals are factoring the growth in demand for veterinary vaccines. 

Future Market Insights projects that the MEA veterinary vaccines market, which is presently valued at US$ 267.3 million, will soar below average to reach US$ 422.9 million value by 2026-end and register a moderate CAGR of 4.7%. The report estimates that lack of resources for collection of samples, questionable potency of vaccines, and absence of harmonised vaccination procedures are limiting the supply and production of veterinary vaccines in the MEA region. Furthermore, ineffectiveness of veterinary vaccines in curing virulent animal diseases indicates shortcomings on epidemiological knowledge faced by MEA’s virology research institutes. 

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-ma-3086

Highest Veterinary Vaccine Sales recorded in Jordan

A regional analysis of the veterinary vaccines market in the Middle East identified Jordan as the most lucrative country for sales of veterinary serums. By the end of 2026, Jordan’s veterinary vaccine market is expected to dominate the MEA region by reaching value of US$ 88 million. The demand for veterinary vaccines will be equally higher in Turkey, while Sudan will witness moderate growth in terms of revenues. Meanwhile, countries such as the United Arab Emirates, Kingdom of Saudi Arabia and Egypt will witness revenue growth at more than 4% CAGR throughout the forecast period.

Based in Jordan, JOVAC is being recognised as one of the leading manufacturers of veterinary vaccines in the Middle East. The veterinary vaccines market in MEA region is also witnessing fervent involvement of European companies such as Bioveta, Inc., Merial, Bayer Healthcare AG, and Ceva. Other key players in the MEA veterinary vaccines market include, Intervac Pvt. Ltd., Zoetis, Elanco, and Merck & Co, Inc. 

Surging Demand for Food & Mouth Disease Vaccination

Prevalence of oral and digestion-related disorders among animals is shaping up the growth in demand for veterinary vaccines across the Middle East. More than 25% of veterinary vaccines revenues amassed from the MEA region during the projection period will be accounted by food and mouth diseases. New Castle disease has also been observed as prominent indicator for administering veterinary vaccines in this region. Moreover, outbreak of Avian influenza in the MEA region is anticipated to attribute more than US$ 80 million revenues by 2026-end. 

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-ma-3086

In the report, titled “Veterinary Vaccines Market: Middle East Industry Analysis and Opportunity Assessment, 2016-2026,” the demand for attenuated live vaccines is predicted to remain high throughout the forecast period. Inactivated vaccines will also gain traction, while revenues garnered from sales of recombinant vaccines, DNA vaccines and toxoid vaccines will grow at a sluggish CAGR. Almost three-fourth of gross revenues amassed from sales of veterinary vaccines in the Middle East will continue to be used for treatment of livestock animals. And, these vaccines are likely to enter the market through veterinary clinics and private veterinary pharmacies. Distribution of veterinary vaccines in the Middle East will also be carried out by hospitals, revenues from which are estimated to surpass US$ 100 million by the end of 2026. 

Global dengue vaccine market revenue is expected to expand at a significant rate owing to a large unmet need

Burdening occurrence of dengue fever across the Asia-Pacific region has prompted the demand for effective vaccines and medications to supress this viral malaise. While several pharmaceutical companies are striving to develop a cure for dengue, the fever’s incidence rate in Asia-Pacific is rising at an alarming rate. A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific. Through 2027, the region will continue to be the largest market for dengue vaccines, procuring a majority revenue share and projecting revenue growth at a 17.4% CAGR.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1763

Future Market Insights also observes Latin America as the second-largest market for dengue vaccines, and is expected to rake in US$ 288.7 Mn towards the end of 2027. The report, titled “Dengue Vaccines Market: Global Industry Analysis and Opportunity Assessment, 2017-2027,” expects that more and more pharmaceutical giants from across the globe will be partaking in the market’s growth in the years to come. Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.

The report further reveals that government institutes will remain the largest end-users of dengue vaccines in the world. Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes. Meanwhile, hospitals will also dominate the market by registering a 17.3% revenue CAGR. The market, at present, will witness sales of the sole of vaccine, Dengvaxia, developed by Sanofi. Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are:

• Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market’s growth at a macroeconomic level
• Live attenuated vaccines are being developed & produced economically, thereby comforting vaccine makers as well as patients
• However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease
• The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1763

On the long run, the global market for dengue vaccines, which is presently valued at close to US$ 250 Mn, will soar vigorously to rake in US$ 1,250.6 Mn revenues by the end of 2027.

Bluetooth connected smart insulin pen segment to register highest market attractiveness index in the near future

Increasing pool of diabetic patients witnessed across the globe has prompted leading manufacturers of medical devices towards development of ground-breaking products. Smart insulin pens are among such devices that have revolutionised the global market for diabetic injection pens. A recent study published by Future Market Insights projects that the global smart insulin pens market, which is currently valued at US$ 0.86 Mn, will expand vigorously at 17.9% CAGR through the end of 2027. During this ten-year forecast period, the global demand for smart insulin pens is estimated to surge rapidly as medical device manufacturers will be actively adopting advanced technologies that deliver cutting-edge devices.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1827

While the parent market – global diabetic injection pens market – is presently worth US$ 4.9 Bn, contribution of revenues arising from global sales of smart insulin pens will remain minimal. Nevertheless, the global smart insulin pens market will bring in more than US$ 4 Mn revenues by the end of 2027. The report, titled “Smart Insulin Pens Market: Global Industry Analysis and Opportunity Assessment, 2017-2027,” also reveals that Europe will emerge as a dominant region for growth of global smart insulin pens market. Sales of smart insulin pens across European countries are anticipated to bring in over US$ 2.4 Mn by end of 2027. Meanwhile, awareness regarding smart insulin pens is expected to rise robustly across the US and Canada. North America’s smart insulin pens market is, thus, estimated to register revenue growth at a staggering 26.7% CAGR. Through 2027, sales of smart insulin pens across Asia-Pacific region are also projected to gain traction, bringing in a little over US$ 1.2 Mn in revenues.

Key Trends Driving the Demand for Smart Insulin Pens

A crucial factor fuelling the global sales of smart insulin pens is higher dependency of patients & medical professionals on data obtained from clinical trials. Conventional devices are unable to offer facilities that are provided through smart insulin pens. The demand for smart insulin pens is also driven by preference of health insurers towards outcome-based compensation models. Moreover, medical device manufacturers are looking at profitable opportunities arising from rising adoption of medical management processes, increasing development of insulin adherence programs, and higher demand for patient-centric devices. It has been estimated that during the forecast period, the global market for smart insulin pens will witness active participation from three medical device manufacturers – Companion Medical Inc., Emperra GmbH E-Health Technologies and Digital Medics Pty Ltd.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1827

The report further reveals that a majority of smart insulin pens sold across the world will be purchased for treatment of type II diabetes. The demand for smart insulin pens among type I diabetics is expected to remain considerably lower, procuring global revenues of just over US$ 700,000. Connectivity of smart insulin pens is also observed as a key aspect impacting the market’s growth. And, the report projects the global smart insulin pens market to remain equally split between Bluetooth and USB-connected pens through the end of 2027. The report also expects clinics and ambulatory surgical centres (ASCs) based across the globe as the largest distribution channels for smart insulin pens. In 2017, close to 88% of global smart insulin pens revenues are likely to be accounted by clinics and ASCs. On the other hand, proliferation of online commercial platforms will also play a key role in distribution of smart insulin pens. Throughout the forecast period, e-Commerce distribution channels are expected to exhibit revenue growth at more than 24% CAGR.

Demand for Varicose Vein Treatment Surges in Parallel with Increasing Prevalence of Obesity

Unattended varicose veins can cause one severe pain through swelling, ulceration, venous eczema, and lipodermatosclerosis. Treating them through appropriate measures becomes quite crucial. One may opt for non-surgical remedies such as sclerotherapy, leg elevation, or alternative invasive techniques such as endovenous laser treatments. Collectively, these therapies can be addressed as varicose vein treatments, medically-practiced in all parts of the world. The demand for such varicose vein treatments is expected to grow in the years to come.

Future Market Insights recently conducted its forecast study on the global market for varicose vein treatments, estimating the market’s current value at just over US$ 500 Mn. The report, titled “Varicose Vein Treatment Market: Global Industry Analysis and Opportunity Assessment, 2016-2026,” projects that rising prevalence of obesity will fuel the incidence rate of varicose veins in the world. Occurrence of varicose vein is medically-proven to be higher among obese people. Along with this, the demand for varicose vein treatments is also expected to grow on the account of effectiveness of the treatments, utilisation of user-friendly devices, and growing emphasis of medical practitioners on ensuring patient safety during critical treatment of varicose veins. Towards the end of 2026, the global market for varicose vein treatment will have reached value of US$ 931.4 Mn, registering a robust growth at 6.4% CAGR.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-2538 

Varicose Vein Treatments: Market Opportunities

Backed with strong clinical evidence, endovenous laser ablation devices are more popular to treat varicose veins. However, compared to other procedures such as foam fillers, vein stripping costs, and blast with electricity, endscopic variceal ligation (EVL) is a costlier treatment alternative. Launch of cost-effective EVL devices will work as a favourable opportunity for new entrants as well as existing players in the market. Decreasing the procedure costs and enhancing the adoption of affordable devices will cumulatively boost the adoption of varicose vein treatments.

Among the wide variety of endovenous laser ablation devices available in the market, some of them may lead to complications such as thrombophlebitis, nerve damage, burns and deep vein thrombosis conditions. There is a potential opportunity for endovenous laser ablation device manufacturers to tap the larger market by offering competitive products that cause lesser complications.

APEJ Varicose Vein Treatment Market to Record Speedy Growth

Apropos the report, more than 40% of the market revenues will remain concentrated in North America, throughout the forecast period. By 2026-end, North America’s varicose vein treatment market will have reached a value of US$ 420 Mn. US-based AngioDynamics, Inc. will be observed as a key player in the market during this period. In terms of revenue growth, the varicose vein treatment market in Asia-Pacific excluding Japan (APEJ) region is projected to be at the forefront. By exhibiting 7% CAGR, the APEJ varicose vein treatment market will witness active participation of Korean medical device manufacturer, Wontech Co., Ltd. Apart from these, Syneron Medical Ltd., Dornier MedTech GmbH, Alma Lasers Ltd., Alna-Medicalsystem GmbH, LSO Medical, Energist Ltd. and intros Medical Laser GmbH are other companies partaking in the growth of global varicose vein treatment market.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-2538

The report further reveals that hospitals and ambulatory surgical centres as end-users will account for larger share of global revenues, while specialised clinics will register fastest revenue growth at 7.2% CAGR. The report also identifies endovenous laser treatment as the dominant varicose vein treatment in the market, procuring revenues worth over US$ 500 Mn by end of 2026.

Rising cases of cancer, orthopaedic and other chronic diseases likely to impact the global teleradiology market

According to National Institute of Cancer, 448.7 new cancer cases per 100,000 men and women are diagnosed each year in the US. Taking into account the gravity of such details, the demand for teleradiology is expected to surge not just in the US, but in regions witnessing higher concurrence of cancer. In its latest report, Future Market Insights assesses that the global demand for teleradiology will soar vigorously in the years to come. And, the report projects that largest share of global teleradiology revenues will be emanating from the US alone. The country will not only account for dominance of North America in the global teleradiology market, but by the end of 2026, US teleradiology revenues will have closed in on US$ 5.5 Bn value. During this period, the US teleradiology market is expected to reflect a sizeable gain of 416 BPS, exhibiting a stellar CAGR of 22.3%. 

According to Future Market Insights, the global market for teleradiology is presently valued at US$ 1.9 Bn, and is anticipated to be worth US$ 13.2 Bn by the end of 2026, reflecting a CAGR of 21%. The report, titled “Teleradiology Market: Global Industry Analysis and Opportunity Assessment, 2016-2026,” has analysed the global teleradiology market by splitting other parts of the world from the US. Dominance of US on the global teleradiology market is expected to remain throughout the forecast. Teleradiology Solutions, Argus Radiology, USARAD Holdings, Inc., TeleDiagnosys Services Pvt. Ltd., Imaging Advantage, Foundation Radiology Group, Direct Radiology, Imaging On Call, LLC, ONRAD, Inc., Rays (Envision Healthcare Company), StatRad LLC, ARIS Radiology, NightShift Radiology, Mednax, Inc., Alta Vista TeleRadiology, and Quality Nighthawk are US-based companies actively participating in the growth of global teleradiology market. 

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1747

However, the report also anticipates higher contribution from Europe and the Asia-Pacific excluding Japan (APEJ) region. By the end of 2026, the teleradiology market in Europe will have reached US$ 2.76 Bn in value, while teleradiology revenues accounted the APEJ region will record fastest growth at 24.6% CAGR. European healthcare companies such as Global Diagnostics (Integral Diagnostics), 4ways Healthcare Limited, Medica Group PLC, Teleconsult Europe, and Telemedicine Clinic are also observed as key market players. The report has also profiled companies such as Everlight Radiology, SRL Diagnostics, and Vital Radiology Services, which are based across the APEJ region. 

Easy Access to Teleradiology Promoting its Adoption

The report has observed that increasing consumer awareness regarding teleradiology & easy accessibility of this technology are boosting the market’s growth at considerable extent. Due to online availability of the radiology series, diagnostic images of complex problems can be shared between professionals within a medical setting. Moreover, local clinicians or radiologists can get opinions from subspecialists in order to make informed decision. Active participation and initiatives taken by various government and non-profit organizations to spread awareness regarding telemedicine worldwide is also expected to fuel growth of the global teleradiology market. 

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1747 

Global Teleradiology Market: Key Research Highlights

• A majority of teleradiologists will be preferring CT-scan as the modality for diagnosis, revenues from which are expected to surge at 23.6% CAGR
• MRI scan and ultrasound scans will also be prominent modes of carrying out teleradiological diagnosis
• While hospitals & clinics, collectively, will remain the largest end-users of teleradiology, the demand for such diagnostic technology is expected to gain traction across ambulatory surgical centres (ASCs)
• By 2026-end, ASCs will account for an estimated 30% share of global teleradiology revenues 

Compression Garments and Stockings Market Estimated to Grow Strongly by 2027

According to a latest report published by Future Market Insights, by the end of 2027, the global compression garments and stockings market is anticipated to reach US$ 3,541.3 Mn in value, reflecting a moderate growth at 4.9% CAGR. The global market for compression garments and stockings, which is currently valued at a little over US$ 2,100 Mn, will witness a steady growth in terms of volumes over the forecast period from 2017 to 2027. Towards the end of this period, more than 46 million units of compression garments and stockings will be sold across the globe. The report estimates that volume-wise growth of the global compression garments and stockings market will exhibit a 5.2% CAGR, after recording global sales of 26.5 million compression garments & stockings in 2016. 

The report, titled “Compression Garments & Stockings Market: Global Industry Analysis and Opportunity Assessment, 2017-2027,” has included multiple factors impacting the growth of global compression garments & stockings market during the forecast period. Growing caseload for varicose vein treatments and orthopaedic surgeries is observed as a key driver boosting the sales of compression garments & stockings. Meanwhile, advancements in fabric and garment designer is serving as a blessing in disguise for compression garment & stocking manufacturers. Moreover, rising sports injuries, increase in the number of orthopaedic surgeries, and rapidly growing obese population witnessed in several parts of the world is boosting the global demand for compression therapy products. 

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-3644

The report has also assessed that compression therapy will remain to be recognized as a gold standard for the treatment of lymphedema, chronic venous insufficiency, and deep vein thrombosis during the forecast period. Compression garments and stockings are easy-to-use, safe, and provides effective treatment in a short time span, which will continue fuelling their sales in the long run. Nonetheless, treatment of vascular diseases with compression therapy products is expensive, and demands greater expenditure for routine follow-ups and out-patient monitoring. 

Global Compression Garments & Stockings Market – Forecast Highlights

• In 2016, more than 90% of the global compression garments and stockings market revenues was accounted by global sales of compression garments
• Through 2027, lower compression garments are pegged to remain in great demand, reflecting a volume CAGR of 5.6%
• Throughout the forecast period, varicose veins will be observed as the largest application, account for half of global revenues by 2027-end
• Wound care application of compression garments and stockings is also expected to gain traction, showcasing a value CAGR of 5.2%
• Towards the end of 2027, more than 15 million compression garments and stockings will be distributed across the globe through hospitals
• In the due course of this forecast period, online sales will be observed as fastest-growing distribution channels, exhibiting a robust volume CAGR of 6.5%
• North America and Western Europe, together, will be at the forefront of expansion of global compression garments and stockings market
• While these two regions account for nearly 70% of the market revenues by 2027-end, the compression garments and stockings markets in Latin America and the Asia-Pacific excluding Japan (APEJ) region will register value CAGRs of 5% and 6.2% respectively 

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-3644

Strict Guidelines Limits the Design Space for Potential Conceptual Ideas

Manufacturing medical compression garments require strict guidelines to be followed. Manufacturers are prioritizing optimal therapeutic efficacy, product reliability and best comfort while producing compression garments and stockings. Faulty products and poorly-designed garments & stockings can cause shearing, a potential problem if the patient has weak skin, a venous ulcer or some other wounds. This constraint limits the design space for potential conceptual ideas as patient safety continues to be the most crucial concern and constraint for manufacturers. The report has profiled leading players in the global compression garments and stockings market, which include 3M, BSN Medical, Nouvelle Inc., Medical Z, medi GmbH & Co KG, Covidien Ltd. (a Medtronic PLC. Company), SIGVARIS, Therafirm, Santemol Group Medical, 2XU Pty. Ltd., and Leonisa, Inc.

Respiratory Devices Market Poised to Expand at a Robust Pace Over 2017 – 2027

In an era of smart technologies, conventional devices are being transformed into more intuitive devices. The respiratory devices market is expected to witness transitions from conventional to smart respiratory devices. The challenges associated with empowering the patient population to manage respiratory disorders such as asthma and COPD is likely to spur the need for more simplified and patient-friendly respiratory devices. According to a latest research by Future Market Insights (FMI), the global respiratory devices market is expected to account for over US$ 34,178.1 Mn in terms of value by the end of 2027. The report on respiratory devices further projects significant growth potential with average year-on-year growth rate pegged at 9.2% through 2027.

Respiratory Devices Market Overview & Global Scenario

According to WHO, around 235 million people suffer from asthma each year globally. This high prevalence of respiratory disorders has also significantly impacted the death ratio owing to the lack of effectiveness of inhalers. In several cases, patients do not use respiratory devices/inhalers properly, which leads to uncontrolled asthma. The improper usage of respiratory devices/inhalers also leads to limited drug infusion to the lungs, which leads to poor disease control and increase in the cost of care. In May 2014, National Review of Asthma Deaths published that 2/3rds of mortalities in the UK could be managed with proper routine check-ups. The growing number of hospital admissions due to the improper usage of respiratory devices/inhalers has accelerated the development of first-generation smart respiratory devices/inhalers. These first-generation smart inhalers are built on Bluetooth-enabled technology, which is used to monitor respiratory devices/inhaler usage, patient data collection and dose reminders. However, these respiratory devices have significant room for further improvement as patients are looking for more integrated solutions that can reduce the size of inhalers.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-794

Respiratory Devices Market: Factors Impacting Growth in Revenue

The growing demand for lightweight and easy to carry portable oxygen concentrators has created the need for innovations in the respiratory devices market. Easy availability of land and other important resources required for production of the respiratory devices with low cost labor the major key players operating in respiratory devices are planning to shift their production facilities to such places, which in turn is expected to change in profit margins of respiratory devices for the company The manufacturers of respiratory devices are investing in product development to drive innovation, which has resulted in the creation of lighter-weight and cost-effective portable oxygen concentrators. Manufacturers of respiratory devices are considering all aspects during the production designing of respiratory devices, which include aesthetics, packaging, noise level, battery life, etc. The company predicts that the portable oxygen concentrators segment in the respiratory devices market will reach US$ 2,061.5 Mn by the end of 2027 with a CAGR of 9.4% over the forecast period.

Increasing preference for in-home respiratory therapy for patients suffering from chronic respiratory disorders or patients being treated for infection, which does not require hospitalization, is likely to boost the demand for home oxygen concentrators in respiratory devices market. This is likely to fuel the global demand for home oxygen concentrators in respiratory devices market. FMI predicts that the home oxygen concentrators segment in the respiratory devices market will grow with a CAGR of 6.9% over the forecast period. In-home ventilation therapy (CPAP & BiPAP) is also gaining popularity among COPD and Obstructive Sleep Apnea (OSA) patients. These types of in-home ventilation therapies have reduced the rate of hospitalisation and the overall cost of treatment.

About the Respiratory Devices Market Report

FMI has segmented the global respiratory devices market into product type, end user and region. In terms of revenue, the positive airway pressure devices segment in the respiratory devices market is expected to hold a significant revenue share over the forecast period. On the other hand, the respiratory devices consumables segment in the respiratory devices market will exhibit faster growth in terms of revenue through 2027.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-794 

FMI’s report tracks some of the key companies in the respiratory devices market, which include Drägerwerk AG & Co. KGaA, Hamilton Medical AG, Massimo Corporation, General Electric Healthcare Limited, Inogen Inc., Teleflex Incorporated, ResMed. Inc., Smiths Medical, Medtronic PLC, Koninklijke Philips N.V., and Fisher & Paykel Healthcare Limited.

Cancer Diagnostics Market is estimated to reach US$ 76.8 Bn by 2026 end

Biotechnology companies are focusing on the development of genotype- and phenotype-specific drugs for chronic diseases such as cancer in order to ensure that next-generation drugs are more efficacious. Multiplex and multi-analyte biomarkers play an important role in the development of translational medicine, which facilitates the translation of basic research into medical advances. In line with this, most pharmaceutical and biotechnology companies are committing to associate their drugs with diagnostic assays, as a number of multiplex biomarkers are directly associated with particular drugs. The growing research and development activities in cancer diagnostics are thus expected to bring revolutionary technologies in cancer diagnostics and in turn would drive the growth of the cancer diagnostics market. Future Market Insights, in its latest report on cancer diagnostics, estimates that the global market for cancer diagnostics is expected to expand 2.3x in terms of revenue by 2026 over 2016 and is estimated to reach US$ 76.8 Bn by 2026 end.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1090

Cancer Diagnostics Market: Overview & Global Market Scenario

Early detection of cancer requires suitable cancer diagnostics procedures to screen the asymptomatic population that is on average risk of cancer, particularly for breast cancer, cervical cancers, colon cancers and melanoma. Increasing awareness towards the early signs and symptoms of cancer among physicians and other healthcare professionals as well as the general population. The inclusion of cancer diagnostics and cancer screening tests to national cancer screening programs by various countries would flourish the global cancer diagnostics market. Regular mammography has been introduced in national cancer programs by major developed countries where the incidence of breast cancer is high. For instance, the U.S. government has included the National Mammography Program to its national cancer screening programs. The government of Australia conducts 3 cancer screening programs viz. BreastScreen Australia, National Cervical Screening Program and National Bowel Cancer Screening Program. Countries in Europe are increasingly adopting HPV DNA screening for cervical cancer as a part of National Cervical Cancer Programs.

Next generation sequencing (NGS) is the most cost-effective, time saving and successful technological advancement in cancer diagnostics in the last three decades. Revolutionary second-generation and third platforms for cancer diagnostics offered by Roche, Illumina and Life Technologies, Pacific Biosciences of California, Inc. are rapidly gaining adoption in the cancer diagnostics market. Many molecular pathology laboratories are transitioning from single molecular PCR protocols to NGS platforms and thus, the market for cancer diagnostics is expected to gain traction.

However, despite the high value propositions of molecular diagnostics for cancer diagnosis, insufficient coverage for costly test procedures discourages majority of patients from pursuing these tests. Moreover, according to the new pricing policy for 2017, CMS has increased rates for several new CPT codes including next-gen sequencing and multi analyte algorithm assays. For instance, CMS increased the cost of next-generation sequencing tests for hereditary breast cancer-related disorders (CPT code 81432) from US$ 623 to US$ 925. It is anticipated that state Medicaid programs will also adjust their prices to reflect Medicare rates. Regulators of CMS as well as private payers are increasingly emphasizing on increasing value and single-source tests having strong evidence of clinical utility. In 2013, CMS discontinued the ‘code stacking’ method for molecular diagnostic reimbursement for cancer. The center has dissolved this policy due to the wrongful exploitation of payment scheme by some of the labs and has stopped paying bills for these tests until the new method of ‘market-based pricing’ comes into action by 2018.

The biopsy segment is likely to dominate the global cancer diagnostics market, primarily due to the introduction of new and advanced techniques such as liquid biopsy and fine needle aspiration for lung cancer. However, the imaging cancer diagnostics segment is expected to gain significant traction due to the high efficiency of imaging technologies such as PET/CT.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1090

Cancer Diagnostics Market: Competitive Analysis

The competition landscape in the global cancer diagnostics market is changing rapidly. Although molecular testing is a hotspot for investment in in vitro diagnostics, the market exhibits awfully delayed growth due to slow returns on investment. In spite of this, all big cancer diagnostics players in the global market are continuously investing in cancer diagnostics, including molecular biomarker testing, NGS, PET scanners, etc. Companies are also investing in the automation of existing molecular assays for cancer diagnostics to foster future growth prospects in the cancer diagnostics market; however, due to the strong competition among companies in the cancer diagnostics market, they may confront price erosion. For instance, Roche, in spite of being a global leader in cancer diagnostics for many years, has lost some ground after huge investments by its global peers such as Thermo Fisher Scientific Inc. and Merck KGaA, among others.

Nerve Repair Market will reach at a CAGR of 11.3% from 2016 to 2027

A damaged nerve can result in severe sensory and motor complications, which may cause severe pain as well as malfunctioning of the appendages. In these conditions, repairing of damaged nerves becomes quite imperative. Fortunately, a range of medical products is available in the market for treating damaged nerves. Nerve protectors, nerve connectors, nerve wraps and nerve grafts are amongst some of the popular products used for nerve repairing. As these products become medically more effective, their demand continues to grow.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-2680

Future Market Insights (FMI) in its latest report titled “Nerve Repair Market: Global Industry Analysis and Opportunity Assessment 2017-2027” identifies that ageing is one of the major factors that increases possibilities of nerve damage. Occurrence of nerve damage is medically-proven to be higher amongst aged people, hence, the rising geriatric population across the globe is fueling the demand for nerve repair products. As per the FMI report, global nerve repair market will ride at an impressive CAGR of 11.3% in terms of revenue during the forecast period (2016-2027). Moreover, increasing government initiatives to spread awareness about new nerve repair treatments and availability of advanced treatment therapies is expected to boost the growth of global nerve repair market over the next couple of years.

Nerve Repair Treatment: Market Opportunities

Currently, most of the leading medical companies that manufacture nerve repair products are mainly concentrated in developed regions such as Europe and North America. Many of the developing countries including Mexico, India, Indonesia and few other countries from the Middle East are yet to witness widespread penetration of the nerve repair biomaterial products. The scope of promoting the products in such emerging markets would definitely bring in lucrative business opportunities for medical companies. Therefore, tapping emerging markets is likely to create opportunities for growth in term of sales of nerve repair products. Some of the leading medical companies are focusing on aspects such as training of physicians and marketing of their products in these developing regions. Axogen, Inc., Baxter International Inc., Stryker Corporation, Integra Lifesciences, Holdings Corp, Neurotex, Ltd. and Polyganics B.V. are some leading medical companies partaking in the growth of global nerve repairing market.

North America Nerve Repair Market to Maintain its Speedy Growth

In 2016, the nerve repair market in North America captured more than 40% share in terms of revenue. The expanding base of geriatric population and rising demand for advanced medical technology in the U.S. continues to create new market opportunities for manufacturers of nerve repair products in the region. Meanwhile, demand for nerve repair products in Japan has been overwhelmingly high in recent years and similar trends are expected to continue throughout the forecast period. In addition, nerve repair market in Japan is expected to expand at an impressive CAGR of 10.8% over the forecast period owing to increasing healthcare awareness and demand for advanced medical technology.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-2680

Additional Highlights of the Report Include:

• Nerve graft is the most popular nerve repairing product type and is estimated to account for around 40.3% revenue share of the global market by 2017-end.
• Repairing of epineural nerves is expected to remain the highest amongst all the types of nerve repair. Towards the end of the assessment period, revenue from epineural nerve repairing is estimated to reach US$ 290.3 Mn.
• Hospitals will remain as the largest end user of nerve repair products and are projected to account for over 61% value share of the market by end of 2027.

Optical Coherence Tomography Market will Register a CAGR of 6.7% through 2027

A significant rise in the occurrence of cardiovascular and ophthalmologic disorders has been recorded in recent years. As a countermeasure, state authorities and private organisations in ophthalmic care are introducing several eye care programs for the general public. Globally, the number of people with eye disorders has increased to a severe level, hence further escalating the need for advanced eye care imaging and treatment. This has been observed as a major factor fuelling the demand for optical coherence tomography of late. A new study conducted by Future Market Insights (FMI) reveals that the global optical coherence tomography market to grow from US$ 660.5 Mn in 2016 to US$ 1,349.1 Mn by 2027-end. This market is expected to expand at a CAGR of 6.7% in terms of revenue between 2017 and 2027. During this ten years of the forecast, the popularity of optical coherence tomography is expected to grow rapidly as medical companies are laying strong emphasis on development of portable devices in order to increase the adoption rate of such imaging technology. 

Global Optical Coherence Tomography Market: Opportunities and Trends

Manufacturers of OCT systems are actively focusing on expanding their existing range of products. Some of the latest OCT systems now come with multi layers analysis of the surface as well as offer higher image resolutions. Moreover, making such systems portable and user-friendly is anticipated to encourage their robust adoption in the near future. Also, players in the global market for optical coherence tomography are expected to benefit from increasing medical and non-medical application of OCT.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-3362

In an attempt to further improve their market position, some of the leading market players are entering into partnership, merger, sales agreement and acquisition with local manufacturers from emerging countries. FMI in its report titled “Optical Coherence Tomography Market: Global Industry Analysis and Opportunity Assessment, 2017–2027” has profiled leading market players such as Leica Microsystems (Sub. Danaher), Optovue Inc., Carl Zeiss Meditec AG, Santec Corporation, Heidelberg Engineering GmbH, OPTOPOL Technology Sp. z o.o. (Sub. Canon Inc.), Topcon Corporation, Michelson Diagnostics Ltd, Tomophase Inc., Moptim Imaging Technique, NIDEK CO., LTD., Sonostar Technologies Co., Limited.

Additional Highlights of the Report Include:

• Preference for spectral domain-OCT is projected to remain relatively higher as compared to other types of OCT throughout the forecast period.
• Application of OCT in ophthalmology is expected to bring in US$ 983.4 Mn in revenues towards the end of 2027.
• Based on end users, hospitals are estimated to account for more than 39% market share over the assessment period.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-3362

Among regions, North America is expected to hold the largest share of the market during the forecast period. By 2017-end, the region’s market is expected to reach a valuation of US$ 232.2 Mn. Meanwhile, the OCT market in Asia-Pacific excluding Japan is expected to witness the highest growth over 2027. Owing to this, a number of leading market players such as Carl Zeiss Meditec AG, Topcon Corporation and Heidelberg Engineering GmbH are increasing their penetration in some of the key countries in the region, especially in China with their high-quality product types and services. 

Global Atopic Dermatitis Treatment Market to Garner U$ 23,992.3 Mn in Revenues by 2027-End

A new report from Future Market Insights reveals that global atopic dermatitis treatment market revenue is set to expand at a CAGR of 12.8% over the forecast period (2017–2027). In recent years, the prevalence of atopic dermatitis has increased to a great extent, leading to higher demand for its treatment. In addition, the arrival of novel drugs and therapeutic options is also facilitating the growth of the global atopic dermatitis treatment market. Towards the end of 2027, the market is expected to reach a valuation of US$ 23,992.3 Mn. This growth will be further driven by continuous research and drug development and the introduction of revised reimbursement policies.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-3097

The report, titled “Atopic Dermatitis Treatment Market: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027” has also analysed the market by splitting it into regional segments. The dominance of North America on the global atopic dermatitis treatment is expected to remain throughout the assessment period. In 2016, the region’s dermatitis treatment market accounted for a revenue share of 30%. The market in the region is anticipated to witness a CAGR of 16.0% to reach a valuation of US$ 10,384 Mn over 2027. Meanwhile, the market is Western Europe will maintain its second position behind North America. Pharma companies in Europe are concentrating on expanding their product portfolio by acquiring smaller companies specialised in dermatology portfolios. The report also projects a considerable growth of the atopic dermatitis treatment market in Asia pacific excluding Japan (APEJ) over the next couple of years.

Additional Highlight of the Report Include:

• By drug class, corticosteroids currently account for the largest revenue share of the market. However, biologic therapy and PDE-4 inhibitor are expected to outsell corticosteroids by the end of forecast period.

• Biologic therapy is projected to account for around 36.4% share of the market over 2027, expanding at a CAGR of 26.4%. During the same period, the revenue share of PDE-4 inhibitor is expected to expand at a staggering CAGR of 33.4%.

• In 2017 and beyond, preference for drug administration using topical procedures will remains significantly high as compared to oral and injectable administration modes. Topical drug administration will account for more than two-third share of the market by 2027-end.

• Hospital pharmacies remain the leading distribution channel despite the rapid proliferation of dermatology clinics. In 2017, hospital pharmacy will represent a market share of 33.1%, which will incur a slight downtrend and settle for 31.4% by the end of 2027.

Some of the leading pharmaceutical companies that have an active participation in the global atopic dermatitis treatment market include: Sanofi SA, Galderma SA, Allergan Plc., Novartis, Bristol-Myers Squibb, Bayer AG, Meda Pharmaceuticals, Astellas Pharma Inc., Anacor Pharmaceutical Inc., Regeneron Pharmaceuticals, Aqua Pharmaceuticals (An Almirall Company), Pfizer, Dow Pharm, Connetics Corporation, Fujisawa Healthcare, Encore Dermatology, LEO Pharma, Velite Pharmaceutical, Biofrontera AG.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-3097

 Many of these market players are implementing strategies such as merger and acquisition in order to enhance their product portfolio. At the same time, increasing numbers collaborations among market players and medical research institutes are leading to new product development. 

Medical Bionic Implants And Exoskeletons Market Estimated to Expand at a Robust CAGR over 2027

The global medical bionic implants and exoskeletons market stood at U$ 454.5 Mn in 2016. It is expected to expand at a CAGR of 7.5% during the period 2017-2027 to reach U$ 1,001.4 Mn. 

Factors such as rising amputation rates, diabetes, arthritis, trauma cases and expanding ageing demographics have led to a higher number of bionic implants and exoskeletons procedures. According to National Center for Health Statistics, 185,000 new amputations are consistently being performed in the U.S every year. Advancement in new robotics technology (mind-controlled bionic limbs & exoskeletons) coupled with 3D printing is also positively impacting the growth of the market. 

Although Future Market Insights maintains a positive outlook on the global medical bionic implants and exoskeletons market, a high cost of the implants, budgetary restraints and inadequate reimbursement policies can hinder the market’s growth. 

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-4254

The key trends that are expected to govern the global medical bionic implants and exoskeletons market in the near future are; 

• Valuable bionic products are increasingly penetrating the emerging markets as they are cost-effective and offer good quality. 

• Rising patient awareness is likely to prevent patients from opting for traditional medical procedures. This, in turn, is further expected to boost the demand for bionic products. 

• Manufacturers are adopting new automated channel systems, computer-navigated and robot-assisted 3D printing technology and smart implants, making bionic implant and exoskeletons procedures more credible and pragmatic for patients. 

Bionic Forelimbs/Hand Bionics Account for Highest Revenue Share 

As per Future Market Insights’ findings, revenues from bionic forelimb/hand bionic implants are currently high. Throughout the forecast period, this segment is expected to account for a considerable revenues share of the market owing to vast improvements that are being made in bionic forelimb/hand functionality. 

By mode, prosthetic bionic is expected to remain the most attractive segment in 2017 and beyond.  This is primarily attributed to the increasing acceptance of bionic prosthetics coupled with rising amputation rates across the globe. 

North America at the Forefront of Global Medical Bionic Implants and Exoskeletons Market  

Availability of technologically advanced bionic limbs and exoskeletons coupled with rising amputation rates among the matured population is facilitating the growth of medical bionic implants and exoskeletons market in North America. In 2016, the region accounted for more than one-third revenue share of the global market. Future Market Insights anticipates that North America will remain the most attractive market for medical bionic limbs and exoskeletons during the assessment period. Meanwhile, the markets in Western Europe and Asia Pacific excluding Japan (APEJ) is expected to record healthy growth rates over 2027. 

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-4254

Manufacturers are consistently trying to innovate, as bionic implants are considered a high margin cutting-edge reconstructive product. Otto Bock Inc., DJO Global Inc., Ossur Corporate, Ekso Bionics, Rex Bionics Ltd., Alter G, ReWalk Robotics are some of the leading players operating in the global medical bionic implants and exoskeletons market.

Continuous Renal Replacement Therapy Market Poised to Expand at a Robust Pace Over 2027

Acute kidney injury (AKI) is a common type of kidney disorder with high morbidity and mortality worldwide. Patients from low-resource regions are more prone to acute kidney injuries. The incidence of acute kidney injuries varies greatly in Asia due to significant variation in climate, geographical attributes, ethnic groups and socioeconomic status. The global continuous renal replacement therapy market was valued at US$ US$ 743 Mn in terms of value in 2016, according to a latest research by Future Market Insights (FMI). The report on continuous renal replacement therapy further projects significant growth potential with average year-on-year growth rate of 7.7% through 2027.

Continuous renal replacement therapy is conducted for blood purification in patients suffering from acute kidney injury who unable to withstand rapid fluid and electrolyte exchange of conventional hemodialysis. Continuous renal replacement therapy involves the removal of blood from the arterial lumen catheter through the peristaltic movement and pushing it through a hemofilter before getting pumped into a patient via a venous lumen of catheter. Rising incidence of acute kidney injuries, multiple organ failure and other renal injuries had increased the demand for dialysis sessions.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/continuous-renal-replacement-therapy-market

Numerous advantages of continuous renal replacement therapy over the conventional dialysis procedure is a primary factor driving the adoption of continuous renal replacement therapy. Conventional dialysis systems are operated manually and all associated tasks are solely controlled by the user or caregiver. However, technological advancements in currently available continuous renal replacement systems allows the automatic management of disease parameters. Hence, most of the problems are being directly handled by automated digital machines, which is not possible in case of conventional systems, thus reducing the labour cost.

To expand their commercial footprint across the globe, several manufacturers of continuous renal replacement therapy are focusing on introducing new technologies and upgrading their existing products along with simultaneous focus on strategic alliances for the sale and promotion of their products. For instance, in 2015, Fresenius Medical Care AG & Co. KGaA launched multi Filtrate PRO, a therapy system for continuous renal replacement therapy for the treatment of acute kidney failure in critically ill patients at intensive care units. Innovations in extracorporeal technologies will play a critical role in the long-term sustainability of continuous renal replacement therapy devices. The advent of continuous renal replacement therapy devices will eventually attract a new patient base. For instance, in September 2017, Baxter International Inc. launched 3-In-1 oXiris Set for sepsis management protocols & continuous renal replacement therapy, which was previously indicated only for continuous renal replacement therapy. The commercialisation of such multimodal devices is expected to enhance the ROI for hospitals. The introduction of novel autonomous CRRT devices will marginally reduce physician intervention and the cost of treatments in intensive care units. The intuitive platform with touch screen and step-by-step automated instructions promotes ease of use during procedures.

Companies are investing in future growth by expanding their healthcare services businesses through acquisitions as well as the purchase of expertise and relevant technologies in the area of research and development. In 2016, Fresenius Medical Care spent US$1.3 Bn on capital expenditures, acquisitions and the purchase of intangible assets minus income from divestments. The majority of capital expenditures were used for equipping existing & new clinics, preserving & expanding production capacity, primarily in North America, Germany, Asia Pacific and France, as well as for dialysis machines made available to customers and for care coordination.

FMI segmented the global continuous renal replacement therapy market into product type, end user & regions. In terms of revenue, the consumables segment is expected to hold a substantial market share over the forecast period. The segment is expected to exhibit a significant CAGR of 8.5% over the forecast period.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1211

FMI’s report covers some of the key companies operating in the continuous renal replacement therapy market, which include Fresenius Medical Care AG & Co. KGaA; Baxter International Inc.; B. Braun Melsungen AG; Medica SpA, Nikkiso Co., Ltd.; Nipro corp.; Toray Medical Co., Ltd.; NxStage Medical, Inc.; Asahi Kasei Corp. and Medtronic plc.